REVIEW

HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma

  • Xiaoguang Wang ,
  • Brittany C. Waschke ,
  • Rachel A Woolaver ,
  • Samantha M. Y. Chen ,
  • Zhangguo Chen ,
  • Jing H. Wang
Expand
  • Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, School of Medicine, 12800 E. 19th Ave, Mail Stop 8333, Aurora, CO 80045, USA

Received date: 03 Dec 2019

Accepted date: 30 Jan 2020

Published date: 15 Jul 2020

Copyright

2020 The Author(s) 2020

Abstract

Immunotherapy has been applied successfully to treat B-cell lymphomas in preclinical models or clinical settings. However, immunotherapy resistance is a major challenge for B-cell lymphoma treatment. To overcome this issue, combinatorial therapeutic strategies have been pursued to achieve a better efficacy for treating B-cell lymphomas. One of such strategies is to combine immunotherapy with histone deacetylase (HDAC) inhibitors. HDAC inhibitors can potentially increase tumor immunogenicity, promote anti-tumor immune responses, or reverse immunosuppressive tumor environments. Thus, the combination of HDAC inhibitors and immunotherapy has drawn much attention in current cancer treatment. However, not all HDAC inhibitors are created equal and their net effects are highly dependent on the specific inhibitors used and the HDACs they target. Hence, we suggest that optimal treatment efficacy requires personalized design and rational combination based on prognostic biomarkers and unique profiles of HDAC inhibitors. Here, we discuss the possible mechanisms by which B-cell lymphomas acquire immunotherapy resistance and the effects of HDAC inhibitors on tumor cells and immune cells that could help overcome immunotherapy resistance.

Cite this article

Xiaoguang Wang , Brittany C. Waschke , Rachel A Woolaver , Samantha M. Y. Chen , Zhangguo Chen , Jing H. Wang . HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma[J]. Protein & Cell, . DOI: 10.1007/s13238-020-00694-x

1
Akimova T,Ge G, Golovina T, Mikheeva T, Wang L, Riley JL, Hancock WW (2010) Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin Immunol 136:348–363

DOI

2
Assouline SE, Nielsen TH, Yu S, Alcaide M, Chong L, MacDonald D, Tosikyan A, Kukreti V, Kezouh A,Petrogiannis-Haliotis T (2016) Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood 128:185–194

DOI

3
Azzaoui I, Uhel F, Rossille D, Pangault C, Dulong J, Le Priol J, Lamy T, Houot R, Le Gouill S, Cartron G (2016) T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloidderived suppressor cells. Blood 128:1081–1092

DOI

4
Beier UH, Wang L, Bhatti TR, Liu Y, Han R, Ge G, Hancock WW (2011) Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs allograft survival. Mol Cell Biol 31:1022–1029

DOI

5
Betsch A, Rutgeerts O, Fevery S, Sprangers B, Verhoef G,Dierickx D, Beckers M (2018) Myeloid-derived suppressor cells in lymphoma: the good, the bad and the ugly. Blood Rev 32:490–498

DOI

6
Bobrowicz M, Dwojak M, Pyrzynska B, Stachura J, Muchowicz A, Berthel E, Dalla-Venezia N, Kozikowski M, Siernicka M, Miazek N (2017) HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood 130:1628–1638

DOI

7
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-A Cancer Journal for Clinicians 68:394–424

DOI

8
Cao K,Wang G, Li W, Zhang L, Wang R, Huang Y, Du L, Jiang J, Wu C, He X (2015) Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity. Oncogene 34:5960–5970

DOI

9
Carey CD, Gusenleitner D, Lipschitz M, Roemer MGM, Stack EC, Gjini E,Hu X, Redd R, Freeman GJ, Neuberg D (2017) Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood 130:2420–2430

DOI

10
Challa-Malladi M, Lieu YK, Califano O, Holmes AB, Bhagat G, Murty VV, Dominguez-Sola D, Pasqualucci L, Dalla-Favera R(2011) Combined genetic inactivation of beta 2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 20:728–740

DOI

11
Chau CH, Steeg PS, Figg WD (2019) Antibody-drug conjugates for cancer. Lancet 394:793–804

DOI

12
Chen R, Frankel P, Popplewell L, Siddiqi T, Ruel N, Rotter A, Thomas SH, Mott M,Nathwani N, Htut M (2015) A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica 100:357–362

DOI

13
Chen Z, Elos MT, Viboolsittiseri SS, Gowan K, Leach SM, Rice M, Eder MD, Jones K, Wang JH (2016) Combined deletion of Xrcc4 and Trp53 in mouse germinal center B cells leads to novel B cell lymphomas with clonal heterogeneity. J Hematol Oncol 9:2

DOI

14
Chen Z, Wang JH (2014) Generation and repair of AID-initiated DNA lesions in B lymphocytes. Front Med 8:201–216

DOI

15
Cheng J, Zhao L, Zhang Y, Qin Y, Guan Y, Zhang T,Liu C, Zhou J(2019) Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies. Front Oncol 9:1237

DOI

16
Chu Y, Yahr A, Ayello J, Cairo MS (2015) Effectively targeting Burkitt lymphoma by anti-CD20 chimeric antigen receptor (CAR) modified expanded natural killer cells combined with a histone deacetylase inhibitor, romidepsin in vitro and in humanized NSG mice. Biol Blood Marrow Transplant 21:S152–S153

DOI

17
Chu Y, Yahr A, Huang B,Ayello J, Barth MS, Cairo M (2017) Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice. Oncoimmunology 6:e1341031

DOI

18
Cycon KA, Mulvaney K, Rimsza LM, Persky D, Murphy SP (2013) Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma. Immunology 140:259–272

DOI

19
de Charette M, Houot R (2018) Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy. Haematologica 103:1256–1268

DOI

20
de Charette M, Marabelle A, Houot R (2016) Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy? Eur J Cancer 68:134–147

DOI

21
de Zoeten EF, Wang L, Butler K, Beier UH, Akimova T, Sai H, Bradner JE, Mazitschek R, Kozikowski AP, Matthias P (2011) Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol 31:2066–2078

DOI

22
Deng S, Hu Q, Zhang H, Yang F, Peng C, Huang C (2019) HDAC3 inhibition upregulates PD-L1 expression in B-cell lymphomas and augments the efficacy of anti-PD-L1 therapy. Mol Cancer Ther 18:900–908

DOI

23
Dias JN, Aguiar SI, Pereira DM, André AS, Gano L, Correia JD, Carrapiço B, Rçtgen B, Malhç R, Peleteiro C (2018) The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma. Oncotarget 9:28586

DOI

24
Diepstra A, Van Imhoff GW, Karim-Kos HE, Van den Berg A,Meerman GJT, Niens M,Nolte IM, Bastiaannet E, Schaapveld M, Vellenga E (2007a) HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin lymphoma. Haematologica 92:40–41

DOI

25
Diepstra A, van Imhoff GW, Karim-Kos HE, van den Berg A, te Meerman GJ, Niens M, Nolte IM, Bastiaannet E,Schaapveld M, Vellenga E (2007b) HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin’s lymphoma. J Clin Oncol 25:3101–3108

DOI

26
Fangazio M,Dominguez-Sola D, Tabbo F, Rossi D, Teruya-Feldstein J,Boldorini R, Gaidano G,Bhagat G, Inghirami G, Pasqualucci L (2014) Genetic mechanisms of immune escape in diffuse large B cell lymphoma. Blood 124:1692

DOI

27
Frys S, Simons Z,Hu Q, Barth MJ, Gu JJ, Mavis C, Skitzki J, Song L, Czuczman MS, Hernandez-Ilizaliturri FJ (2015) Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents. Br J Haematol 169:506–519

DOI

28
Garrido F, Aptsiauri N, Doorduijn EM, Lora AMG, van Hall T (2016) The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol 39:44–51

DOI

29
Garrido F,Cabrera T, Aptsiauri N (2010) “Hard” and “soft” lesions underlying the HLA Class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 127:249–256

DOI

30
Gil VS, Bhagat G, Howell L, Zhang J,Kim CH, Stengel S, Vega F, Zelent A, Petrie K (2016) Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice. Dis Model Mech 9:1483–1495

DOI

31
Grunewald CM, Schulz WA, Skowron MA, Hoffmann MJ, Niegisch G (2018) Tumor immunotherapy-the potential of epigenetic drugs to overcome resistance. Transl Cancer Res 7:1151–1160

DOI

32
Gryder BE, Sodji QH, Oyelere AK (2012) Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 4:505–524

DOI

33
Hiraga J,Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, Kiyoi H, Kinoshita T, Naoe T (2009) Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 113:4885–4893

DOI

34
Huang HL, Peng CY, Lai MJ, Chen CH, Lee HY, Wang JC, Liou JP, Pan SL, Teng CM (2015) Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo. Oncotarget 6:4976–4991

DOI

35
Huang RH, Zhang XW, Min ZJ, Shadia AS, Yang SE, Liu XJ (2018) MGCD0103 induces apoptosis and simultaneously increases the expression of NF-kappa B and PD-L1 in classical Hodgkin’s lymphoma. Exp Ther Med 16:3827–3834

DOI

36
Insinga A, Monestiroli S,Ronzoni S,Gelmetti V, Marchesi F,Viale A, Altucci L, Nervi C, Minucci S, Pelicci PG (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11:71–76

DOI

37
Jiang Y, Ortega-Molina A, Geng H, Ying HY, Hatzi K, Parsa S, McNally D, Wang L, Doane AS, Agirre X (2017) CREBBP inactivation promotes the development of HDAC3-dependent lymphomas. Cancer Discov 7:38–53

DOI

38
Johnson NA, Boyle M, Bashashati A, Leach S, Brooks-Wilson A, Sehn LH, Chhanabhai M, Brinkman RR, Connors JM, Weng AP (2009) Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood 113:3773–3780

DOI

39
Khodadoust MS, Olsson N, Chen B, Sworder B, Shree T, Liu CL, Zhang L, Czerwinski DK, Davis MM, Levy R (2019) B-cell lymphomas present immunoglobulin neoantigens. Blood 133:878–881

DOI

40
Khodadoust MS, Olsson N,Wagar LE, Haabeth OA, Chen B, Swaminathan K, Rawson K, Liu CL, Steiner D, Lund P (2017) Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature 543:723–727

DOI

41
Kim K,Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B (2014) Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci USA 111:11774–11779

DOI

42
Klein JM, Henke A, Sauer M, Bessler M, Reiners KS, Engert A, Hansen HP, von Strandmann EP (2013) The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines. PLoS ONE 8: e79502

DOI

43
Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ (2014) HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget 5:6558–6572

DOI

44
Kuppers R (2005) Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 5:251–262

DOI

45
Lee SH, Yoo C, Im S, Jung JH, Choi HJ, Yoo J (2014) Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significance. Int J Med Sci 11:994–1000

DOI

46
Liu X,Phillips AJ, Ungermannova D, Nasveschuk CG, Zhang G (2013). Macrocyclic compounds useful as inhibitors of histone deacetylases. US Patent 20130203681A1 (US Patent 20130203681A1.)

47
Lucas DM, Davis ME, Parthun MR, Mone AP, Kitada S, Cunningham KD, Flax EL, Wickham J, Reed JC, Byrd JC (2004) The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 18:1207–1214

DOI

48
Maloney DG (2012) Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 367:878–878

DOI

49
McCaw TR, Randall TD, Forero A, Buchsbaum DJ (2017) Modulation of antitumor immunity with histone deacetylase inhibitors. Immunotherapy 9:1359–1372

DOI

50
Merryman RW, Armand P,Wright KT, Rodig SJ (2017) Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv 1:2643–2654

DOI

51
Moreira JM, Scheipers P, Sorensen P (2003) The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer 3:30

DOI

52
Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T (2000) Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102:553–563

DOI

53
Murphy K, Weaver C (2017) Janeway’s immunobiology, 9th edn. Garland Science, New York,pp 1–904

54
Nakata S,Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T (2004) Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23:6261–6271

DOI

55
Nijland M, Veenstra RN, Visser L, Xu CH, Kushekhar K, van Imhoff GW, Kluin PM, van den Berg A, Diepstra A (2017) HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy? Oncoimmunology 6:e1295202

DOI

56
Ok CY, Young KH (2017) Targeting the programmed death-1 pathway in lymphoid neoplasms. Cancer Treat Rev 54:99–109

DOI

57
Olejniczak SH, Stewart CC, Donohue K, Czuczman MS (2006) A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest 35:93–114

DOI

58
Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378:449–459

DOI

59
Perez-Duran P, de Yebenes VG, Ramiro AR (2007) Oncogenic events triggered by AID, the adverse effect of antibody diversification. Carcinogenesis 28:2427–2433

DOI

60
Rimsza LM, Farinha P,Fuchs DA, Masoudi H, Connors JM, Gascoyne RD (2007) HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. Leukemia Lymphoma 48:542–546

DOI

61
Rimsza LM, LeBlanc ML, Unger JM, Miller TP, Grogan TM, Persky DO, Martel RR, Sabalos CM, Seligmann B, Braziel RM (2008) Gene expression predicts overall survival in paraffinembedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 112:3425–3433

DOI

62
Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, Weisenberger DD, Chan WC, Muller-Hermelink HK, Jaffe ES (2004) Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 103:4251–4258

DOI

63
Roberts RA, Wright G, Rosenwald AR, Jaramillo MA, Grogan TM, Miller TP, Frutiger Y, Chan WC, Gascoyne RD, Ott G (2006) Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood 108:311–318

DOI

64
Roemer MGM, Advani RH, Redd RA, Pinkus GS, Natkunam Y, Ligon AH, Connelly CF, Pak CJ, Carey CD, Daadi SE (2016) Classical Hodgkin Lymphoma with reduced beta M-2/MHC class I expression is associated with inferior outcome independent of 9p24.1 status. Cancer Immunol Res 4:910–916

DOI

65
Ropero S, Esteller M(2007) The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1:19–25

DOI

66
Rosborough BR, Castellaneta A, Natarajan S, Thomson AW, Turnquist HR (2012) Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo. J Leukoc Biol 91:701–709

DOI

67
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Staudt LM (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937–1947

DOI

68
Roussel M, Irish JM, Menard C, Lhomme F,Tarte K, Fest T (2017) Regulatory myeloid cells: an underexplored continent in B-cell lymphomas. Cancer Immunol Immunother 66:1103–1111

DOI

69
Sahakian E, Powers JJ, Chen J,Deng SL, Cheng F, Distler A, Woods DM, Rock-Klotz J, Sodre AL, Youn JI (2015) Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Mol Immunol 63:579–585

DOI

70
Scott DW, Gascoyne RD (2014) The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 14:517–534

DOI

71
Serafini P, Mgebroff S, Noonan K, Borrello I (2008) Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 68:5439–5449

DOI

72
Sermer D,Pasqualucci L, Wendel HG, Melnick A, Younes A (2019) Emerging epigenetic-modulating therapies in lymphoma. Nat Rev Clin Oncol 16:494–507

DOI

73
Shah NN, Maatman T, Hari P, Johnson B (2019) Multi Targeted CART Cell Therapies for B-Cell Malignancies. Front Oncol 9:146

DOI

74
Shalabi H, Kraft IL, Wang HW, Yuan CM, Yates B, Delbrook C, Zimbelman JD, Giller R, Stetler-Stevenson M, Jaffe ES (2018) Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. Haematologica 103:e215–e218

DOI

75
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168:707–723

DOI

76
Shimizu R, Kikuchi J, Wada T, Ozawa K, Kano Y,Furukawa Y (2010) HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia 24:1760–1768

DOI

77
Smahel M (2017) PD-1/PD-L1 blockade therapy for tumors with downregulated MHC class I expression. Int J Mol Sci 18:1331

DOI

78
Tang HD, Liang Y, Anders RA, Taube JM, Qiu XY, Mulgaonkar A, Liu X, Harrington SM, Guo JY, Xin YC (2018) PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Investig 128:580–588

DOI

79
Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, Li B, Turka LA, Olson EN, Greene MI (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 13:1299–1307

DOI

80
Taori K, Paul VJ, Luesch H (2008) Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J Am Chem Soc 130:1806–1807

DOI

81
Thurn KT, Thomas S, Moore A, Munster PN (2011) Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 7:263–283

DOI

82
Tiper IV, Webb TJ (2016) Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma. Cancer Immunol Immunother 65:1411–1421

DOI

83
Torres-Collad AX, Jazirehi AR (2018) Overcoming resistance of human non-Hodgkin’s lymphoma to CD19-CAR CTL therapy by celecoxib and histone deacetylase inhibitors. Cancers 10:200

DOI

84
Tsai PC, Hernandez-Ilizaliturri FJ, Bangia N, Olejniczak SH, Czuczman MS (2012) Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clin Cancer Res 18:1039–1050

DOI

85
Wang JH (2013) The role of activation-induced deaminase in antibody diversification and genomic instability. Immunol Res 55:287–297

DOI

86
Wang JH, Alt FW, Gostissa M, Datta A, Murphy M, Alimzhanov MB, Coakley KM, Rajewsky K, Manis JP, Yan CT (2008) Oncogenic transformation in the absence of Xrcc4 targets peripheral B cells that have undergone editing and switching. J Exp Med 205:3079–3090

DOI

87
Wang JH, Gostissa M, Yan CT, Goff P, Hickernell T, Hansen E, Difilippantonio S, Wesemann DR, Zarrin AA, Rajewsky K (2009) Mechanisms promoting translocations in editing and switching peripheral B cells. Nature 460:231–U294

DOI

88
Wang XG, Waschke BC, Woolaver RA, Chen ZG, Zhang G,Piscopio AD, Liu XD, Wang JH (2019) Histone deacetylase inhibition sensitizes PD1 blockade-resistant B-cell lymphomas. Cancer Immunol Res 7:1318–1331

DOI

89
West AC, Mattarollo SR, Shortt J, Cluse LA, Christiansen AJ, Smyth MJ, Johnstone RW (2013) An intact immune system is required for the anticancer activities of histone deacetylase inhibitors. Cancer Res 73:7265–7276

DOI

90
Woods DM, Sodre AL, Sarnaik A, Sotomayor EM, Weber J (2015) Class I HDAC inhibition upregulates PD-1 ligands in melanoma and increases the efficacy of PD-1 blockade. Cancer Res 3:1375–1385

DOI

91
Xiao H, Jiao J, Wang L, O’Brien S, Newick K, Wang LC, Falkensammer E, Liu Y, Han R, Kapoor V (2016) HDAC5 controls the functions of Foxp3(+) T-regulatory and CD8(+) T cells. Int J Cancer 138:2477–2486

DOI

92
Xu-Monette ZY, Zhou J, Young KH (2018) PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 131:68–83

DOI

93
Yi M, Qin S, Zhao W, Yu S, Chu Q, Wu K (2018) The role of neoantigen in immune checkpoint blockade therapy. Exp Hematol Oncol 7:28

DOI

94
Ying Y, Taori K, Kim H, Hong J, Luesch H (2008) Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. J Am Chem Soc 130:8455–8459

DOI

95
Yoon S, Eom GH (2016) HDAC and HDAC inhibitor: from cancer to cardiovascular diseases. Chonnam Med J 52:1–11

DOI

96
Youn JI, Kumar V, Collazo M, Nefedova Y,Condamine T, Cheng P, Villagra A, Antonia S, McCaffrey JC, Fishman M (2013) Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol 14:211–220

DOI

97
Zain J, O’Connor OA (2010) Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. Invest New Drugs 28 (Suppl 1):S58–S78

DOI

98
Zhou H, Luo YL, Zhu S, Wang X,Zhao YN, Ou XJ, Zhang T, Ma XL (2018) The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies: a meta-analysis. BMC Cancer 18:929

DOI

Outlines

/